YMAB
Y-mAbs Therapeutics, Inc
Price:  
4.30 
USD
Volume:  
81,293.00
United States | Biotechnology
Valuation
Overview
Financials
Forecast
Compare
Historical Price
SolvencyDividends
Transactions
People

YMAB EV/EBITDA

-320.1%
Upside

As of 2025-07-07, the EV/EBITDA ratio of Y-mAbs Therapeutics, Inc (YMAB) is -5.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. YMAB's latest enterprise value is 134.39 mil USD. YMAB's TTM EBITDA according to its financial statements is -26.56 mil USD. Dividing these 2 quantities gives us the above YMAB EV/EBITDA ratio.

Note: valuation result may not be accurate due to the company's negative EBITDA.

Range Selected
Trailing P/E multiples 12.0x - 13.8x 13.2x
Forward P/E multiples 18.9x - 28.5x 23.6x
Fair Price (9.73) - (6.75) (9.46)
Upside -326.3% - -257.0% -320.1%
4.30 USD
Stock Price
(9.46) USD
Fair Price

YMAB EV/EBITDA - Historical EV/EBITDA Data

Date EV/EBITDA
2025-07-03 -5.06
2025-07-02 -4.99
2025-07-01 -5.25
2025-06-30 -5.42
2025-06-27 -5.74
2025-06-26 -5.91
2025-06-25 -6.10
2025-06-24 -6.47
2025-06-23 -5.78
2025-06-20 -5.25
2025-06-18 -5.62
2025-06-17 -5.91
2025-06-16 -6.15
2025-06-13 -5.76
2025-06-12 -5.62
2025-06-11 -6.13
2025-06-10 -6.44
2025-06-09 -6.39
2025-06-06 -6.71
2025-06-05 -6.42
2025-06-04 -6.18
2025-06-03 -6.03
2025-06-02 -5.81
2025-05-30 -5.57
2025-05-29 -5.83
2025-05-28 -5.60
2025-05-27 -5.25
2025-05-23 -5.09
2025-05-22 -4.77
2025-05-21 -4.72
2025-05-20 -4.94
2025-05-19 -4.84
2025-05-16 -4.72
2025-05-15 -4.31
2025-05-14 -3.93
2025-05-13 -4.82
2025-05-12 -4.67
2025-05-09 -4.36
2025-05-08 -4.62
2025-05-07 -4.34
2025-05-06 -4.31
2025-05-05 -4.97
2025-05-02 -5.25
2025-05-01 -4.74
2025-04-30 -4.97
2025-04-29 -4.89
2025-04-28 -4.94
2025-04-25 -4.72
2025-04-24 -4.77
2025-04-23 -4.75